Renaissance Technologies LLC Buys Shares of 29,000 Edwards Lifesciences Corporation $EW

Renaissance Technologies LLC bought a new stake in Edwards Lifesciences Corporation (NYSE:EW) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 29,000 shares of the medical research company’s stock, valued at approximately $2,322,000.

A number of other institutional investors have also recently made changes to their positions in EW. State Street Corp increased its position in shares of Edwards Lifesciences by 1.5% during the fourth quarter. State Street Corp now owns 25,991,524 shares of the medical research company’s stock worth $2,215,777,000 after purchasing an additional 371,892 shares in the last quarter. Wellington Management Group LLP lifted its holdings in Edwards Lifesciences by 4.8% in the 4th quarter. Wellington Management Group LLP now owns 21,793,949 shares of the medical research company’s stock valued at $1,857,934,000 after purchasing an additional 989,533 shares in the last quarter. Norges Bank acquired a new stake in Edwards Lifesciences during the 4th quarter worth $803,686,000. Morgan Stanley boosted its stake in Edwards Lifesciences by 12.4% during the 4th quarter. Morgan Stanley now owns 7,314,292 shares of the medical research company’s stock worth $623,544,000 after purchasing an additional 804,942 shares during the last quarter. Finally, Marshall Wace LLP grew its holdings in shares of Edwards Lifesciences by 66.1% during the fourth quarter. Marshall Wace LLP now owns 5,925,627 shares of the medical research company’s stock worth $505,160,000 after buying an additional 2,359,128 shares in the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the stock. Leerink Partners upgraded shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating and increased their target price for the company from $87.00 to $101.00 in a research report on Friday, July 24th. Citigroup boosted their price target on shares of Edwards Lifesciences from $101.00 to $110.00 and gave the stock a “buy” rating in a research report on Wednesday, July 8th. Barclays reaffirmed an “overweight” rating and set a $110.00 price objective (up from $104.00) on shares of Edwards Lifesciences in a research note on Monday, April 27th. TD Cowen reiterated a “buy” rating on shares of Edwards Lifesciences in a report on Tuesday, July 21st. Finally, BTIG Research raised their target price on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the stock a “buy” rating in a research note on Tuesday, June 30th. Seventeen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $100.27.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 620 shares of the business’s stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $81.14, for a total transaction of $50,306.80. Following the sale, the vice president directly owned 40,411 shares in the company, valued at $3,278,948.54. This represents a 1.51% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 568 shares of the stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $86.08, for a total transaction of $48,893.44. Following the sale, the senior vice president directly owned 15,334 shares in the company, valued at $1,319,950.72. This represents a 3.57% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 43,539 shares of company stock valued at $3,685,364 in the last three months. 0.31% of the stock is owned by corporate insiders.

Edwards Lifesciences Stock Up 2.6%

Edwards Lifesciences stock opened at $92.01 on Tuesday. The company has a market capitalization of $52.98 billion, a PE ratio of 52.88, a price-to-earnings-growth ratio of 2.25 and a beta of 0.85. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.77 and a current ratio of 4.52. Edwards Lifesciences Corporation has a fifty-two week low of $72.30 and a fifty-two week high of $96.29. The firm has a 50 day moving average price of $88.26 and a 200 day moving average price of $84.14.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The business had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.70 billion. The company’s quarterly revenue was up 13.6% on a year-over-year basis. During the same period last year, the business posted $0.67 earnings per share. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Research analysts expect that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.